Chronic lymphocytic leukaemia (CLL) is a rapidly progressing field in haemato-oncology. The EHA 2022 meeting again provided an update on major clinical trials, the prognostic impact of TP53 mutation in the era of BCL2inh, new insights into the role of marrow microenvironment in the course of the disease, new approaches to Richter’ syndrome and many new promising drugs. The oral presentations about this topic, with practical importance for the clinicians, are covered in this article.

(BELG J HEMATOL 2022;13(5):200–6)